Skip to content
drillr.ai
Sign up

301393.SZ

Suzhou Highfine Biotech Co., Ltd.

SZSE · C 制造业 · CN

CNY 54.67
+3.35%
Ask drillr

  • Oct 23, 2026, 08:17 UTC

    Haofan Bio reported first-nine-month 2026 revenue of RMB 590 million, up 35.67% year over year, and net profit of RMB 108 million, up 8.76%.

    Source:

  • Oct 23, 2026, 08:17 UTC

    Haofan Bio reported third-quarter 2026 revenue of RMB 211 million, up 28.06% year over year, and net profit of RMB 37.1889 million, up 59.24%.

    Source:

  • Aug 24, 2026, 07:56 UTC

    Haofan Biotech announced its first-half 2026 results: revenue of 379 million yuan, up 40.30% year-on-year; net profit attributable to shareholders of 70.7463 million yuan, down 6.77% year-on-year.

    Source:

  • Jul 30, 2026, 08:39 UTC

    Hangzhou First, a controlled subsidiary of Haofan Biotech, was prosecuted by the procuratorate for environmental pollution crimes.

    Source:

  • Jul 7, 2026, 08:26 UTC

    Haofan Biotech announced that 1,863,000 pre-IPO shares will be unlocked and become tradable on July 13, 2026.

    Source: